← Browse by Condition
Medical Condition

liposarcoma

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 1, Phase 2, Phase 2

ClinicalMetric tracks all active clinical trials for liposarcoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — liposarcoma Clinical Trials

How many clinical trials are currently recruiting for liposarcoma?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for liposarcoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for liposarcoma?
liposarcoma research spans Phase 1 (2 trials), Phase 2 (3 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a liposarcoma clinical trial?
Eligibility criteria for liposarcoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
2
Phase 2
3
Top Sponsors
Ascentage Pharma Group Inc. 1 trial
Memorial Sloan Kettering Cancer Center 1 trial
Oslo University Hospital 1 trial

Recruiting Clinical Trials

NCT04785196 Phase 1, Phase 2
Recruiting
APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors
Enrollment
95 pts
Location
China
Sponsor
Ascentage Pharma Group Inc.
View Trial →
NCT06843967 Phase 1, Phase 2
Recruiting
A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
Enrollment
54 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance...
View Trial →
NCT07169344 Phase 2
Recruiting
Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma
Enrollment
110 pts
Location
Norway
Sponsor
Oslo University Hospital
View Trial →

Related Conditions

advanced solid tumor (1) well differentiated liposarcoma (1) dedifferentiated liposarcoma (1) myxoid liposarcoma (1) round cell liposarcoma (1) myxoid pleomorphic liposarcoma (1) pleomorphic liposarcoma (1) unresectable liposarcoma (1) unresectable dedifferentiated liposarcoma (1) soft tissue sarcoma excluding gist (1) soft tissue sarcoma adult (1) soft tissue sarcoma of the trunk and extremities (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology